36 Participants Needed

OKI-179 + Binimetinib for Melanoma

Recruiting at 13 trial locations
OI
Overseen ByOnkure, Inc.
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a combination of two oral medications, OKI-179 and binimetinib, in patients with specific genetic mutations in their cancer. It targets those with RAS pathway mutations and NRAS-mutated Melanoma. The treatment works by blocking signals that help cancer cells grow and divide. Binimetinib is a selective MEK1/2 inhibitor approved in 2018 for the treatment of metastatic melanomas with BRAF and NRAS mutations.

Who Is on the Research Team?

Ryan J. Sullivan, MD - Mass General ...

Ryan Sullivan, MD

Principal Investigator

Massachusetts General Hospital

Are You a Good Fit for This Trial?

This trial is for adults with advanced solid tumors in the RAS pathway or NRAS-mutated melanoma. They must have normal organ and marrow function, be able to swallow oral meds, and not be pregnant or nursing. Exclusions include hypersensitivity to MEK inhibitors, certain eye conditions, uncontrolled heart disease, severe infections like HIV/AIDS, recent major surgery or chemotherapy.

Inclusion Criteria

I have previously been treated with or am ineligible for PD-1/PD-L1 therapy.
My solid tumor hasn't responded to standard treatments, or there are none available, or I refuse them.
My bilirubin levels are normal or slightly higher due to Gilbert's syndrome.
See 16 more

Exclusion Criteria

I have a muscle disorder that causes high CPK levels.
My high blood pressure is not controlled by medication.
I am not pregnant or nursing.
See 21 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment Phase 1b

Participants with activating mutations in the RAS pathway receive a combination of oral OKI-179 and binimetinib

1.5 years
Regular visits for monitoring and assessment

Treatment Phase 2

Participants with NRAS-mutated Melanoma receive a combination of oral OKI-179 and binimetinib

3 years
Regular visits for monitoring and assessment

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Binimetinib
  • OKI-179
Trial Overview The NAUTILUS study tests OKI-179 combined with binimetinib on patients with specific mutations in their tumors. Phase 1b focuses on various solid tumors while Phase 2 targets NRAS-mutated melanoma specifically. It's an open-label study where everyone knows what treatment they're getting.
How Is the Trial Designed?
1Treatment groups
Experimental Treatment
Group I: OKI-179 + binimetinibExperimental Treatment1 Intervention

Binimetinib is already approved in United States, European Union, Canada, Japan for the following indications:

πŸ‡ΊπŸ‡Έ
Approved in United States as Mektovi for:
  • Unresectable or metastatic melanoma with a BRAF V600E or V600K mutation
πŸ‡ͺπŸ‡Ί
Approved in European Union as Mektovi for:
  • Unresectable or metastatic melanoma with a BRAF V600 mutation
πŸ‡¨πŸ‡¦
Approved in Canada as Mektovi for:
  • Unresectable or metastatic melanoma with a BRAF V600E or V600K mutation
πŸ‡―πŸ‡΅
Approved in Japan as Mektovi for:
  • Unresectable or metastatic melanoma with a BRAF V600 mutation

Find a Clinic Near You

Who Is Running the Clinical Trial?

OnKure, Inc.

Lead Sponsor

Trials
3
Recruited
220+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of ServiceΒ·Privacy PolicyΒ·CookiesΒ·Security